<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01896635</url>
  </required_header>
  <id_info>
    <org_study_id>FOCUS</org_study_id>
    <nct_id>NCT01896635</nct_id>
  </id_info>
  <brief_title>Faecal Microbiota Transplantation in Ulcerative Colitis</brief_title>
  <acronym>FOCUS</acronym>
  <official_title>Faecal Microbiota Transplantation for Chronic Active Ulcerative Colitis - A Randomised Double Blind Controlled Study of Efficacy &amp; Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of New South Wales</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of New South Wales</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether fecal microbiota transplantation (FMT) is
      safe and efficacious in the treatment of chronic active ulcerative colitis (UC) by conducting
      a randomised controlled trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study involves the assessment of the safety and efficacy of FMT in the treatment and
      induction of remission for patients with mild to moderate ulcerative colitis. It is a double
      blind study with patients randomised in a 1:1 manner to either active or placebo therapy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Clinical remission &amp; Endoscopic remission / response as measured by Mayo subscores</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical remission as measured by Mayo subscores</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response as measured by Mayo subscores</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic healing as measured by UCEIS</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure rate as defined by Mayo subscores</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by IBDQ</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as measured by adverse event data</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Ulcerative Colitis</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>FMT infusions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FMT infusions constituted from stool provided by healthy, screened donors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo infusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FMT infusions</intervention_name>
    <description>Active FMT derived from healthy anonymous pre-screened donors</description>
    <arm_group_label>FMT infusions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo infusion</intervention_name>
    <description>Placebo infusion not containing any donor microbial material</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ulcerative colitis &gt;3 months duration

          -  Active mild-moderate ulcerative colitis (Mayo 4-10)

          -  Ulcerative colitis of any extent except isolated proctitis &lt; 5cm

          -  Live within driving distance of clinical site (to attend multiple study visits)

        Exclusion Criteria:

          -  Pregnancy

          -  Active gastrointestinal infection

          -  Other gastrointestinal disease / comorbidities

          -  Prior colonic surgery

          -  Recent antibiotic or probiotic use

          -  Prednisone &gt; 20mg

          -  Monoclonal antibody immunosuppressive therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hazel Mitchell, BSc PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New South Wales</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alissa Walsh, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Vincent's Hospital, Sydney</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johan van den Bogaerde, MBChB PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nambour General Hospital, Queensland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Douglas Samuel, MBBS MMed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bankstown-Lidcombe Hospital, Sydney</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nadeem O Kaakoush, BSc PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New South Wales</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Kamm, MBBS MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Melbourne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bankstown-Lidcombe Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2200</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nambour General Hospital</name>
      <address>
        <city>Nambour</city>
        <state>Queensland</state>
        <zip>4560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2013</study_first_submitted>
  <study_first_submitted_qc>July 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of New South Wales</investigator_affiliation>
    <investigator_full_name>Dr. Sudarshan Paramsothy</investigator_full_name>
    <investigator_title>Gastroenterologist / PhD candidate</investigator_title>
  </responsible_party>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>Fecal Transplantation</keyword>
  <keyword>Fecal Microbiota Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

